Tricyclic antidepressants as long-acting local anesthetics.
Amitriptyline, nortriptyline, imipramine, doxepin, desipramine, protriptyline, trimipramine, and maprotiline are tricyclic antidepressants (TCAs) used orally in treating major depressive disorders. Recent studies showed that amitriptyline is more potent in blocking the sciatic nerve functions in vivo by local injection than bupivacaine, a long-acting local anesthetic. We therefore tested whether various TCAs could likewise act as local anesthetics in vivo after single injection via the rat sciatic notch. The duration of complete sciatic nerve blockade by TCAs and the time to reach full recovery were measured with neurobehavioral assays and compared with results from bupivacaine. Amitriptyline, doxepin, and imipramine at 5mM elicited a longer complete sciatic nerve blockade than did bupivacaine at 15.4mM (0.5%), whereas trimipramine and desipramine at 5mM produced a shorter blockade. In contrast, nortriptyline, protriptyline, and maprotiline failed to elicit complete sciatic nerve blockade. Thus, TCAs have very different efficacy as local anesthetics in vivo. The duration of rat sciatic nerve blockade in vivo by TCAs is not well correlated with the 50% inhibitory concentration (IC(50)) of TCAs in blocking human cardiac Nav1.5 Na(+) channels expressed in human embryonic kidney cells. With this in vitro expression system, TCAs appear more potent than bupivacaine as Na(+) channel blockers in Nav1.5 Na(+) channels. We suggest that the ability of TCAs to pass through various membrane barriers within peripheral nerve trunks is crucial to their local anesthetic efficacy in vivo. TCAs with a tertiary amine appear more effective in penetrating these membrane barriers than TCAs with a secondary amine.
Department of Anesthesia, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115 USA.
Yukari
Y
Sudoh
Elaine Elliott
EE
Cahoon
Peter
P
Gerner
Ging Kuo
GK
Wang
D000588:Amines / Q000737:chemistry / Q000145:classification; D000779:Anesthetics, Local / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology* / Q000627:therapeutic use; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D004316:Doxepin / Q000494:pharmacology / Q000627:therapeutic use; D017097:Electric Impedance; D004622:Embryo, Mammalian; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D009043:Motor Activity / Q000187:drug effects; D009460:Neurologic Examination / Q000187:drug effects; D009661:Nortriptyline / Q000494:pharmacology / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy; D010147:Pain Measurement / Q000379:methods; D018408:Patch-Clamp Techniques; D011434:Proprioception / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function / Q000187:drug effects; D012584:Sciatic Nerve / Q000187:drug effects*; D019966:Substance-Related Disorders; D013997:Time Factors; D014162:Transfection / Q000379:methods
D000588:Amines; D000779:Anesthetics, Local; D000929:Antidepressive Agents, Tricyclic; D004316:Doxepin; D009661:Nortriptyline